磷酸化ERK是索拉非尼与MEK抑制剂合成致死联合方案在肝癌中应答的生物标志物
研究通过CRISPR-Cas9合成致死筛选发现抑制ERK2可增敏索拉非尼,MEK或ERK抑制剂在p-ERK高水平肝癌细胞中体外及体内协同逆转索拉非尼无应答,约30%肝癌高表达基础p-ERK,最可能从该联合治疗中获益。
要点
- 抑制ERK2(MAPK1)可增敏多种肝癌细胞系对索拉非尼的应答。
- MEK或ERK抑制剂通过协同抑制ERK激酶活性,在p-ERK高水平肝癌中逆转索拉非尼无应答。
- 约30%肝癌具有高基础p-ERK水平,最可能从索拉非尼联合MEK抑制剂中获益。
核心结论
- 研究提供了一种肝癌联合治疗策略,并提示高基础p-ERK水平的肿瘤最可能从索拉非尼联合MEK抑制剂治疗中获益。
研究设计与样本
- 研究采用基于CRISPR-Cas9的合成致死筛选寻找与索拉非尼协同的激酶,并用caspase-3/7凋亡实验和蛋白质印迹分析索拉非尼与司美替尼的协同效应及p-ERK。
- p-ERK通过免疫组化分析含78例肝癌标本的组织芯片测定,联合方案的体内效应在两个异种移植模型中评估。
主要发现
- 抑制ERK2(MAPK1)使多种肝癌细胞系对索拉非尼敏感。
- 抑制MEK(MEK1/2 [MAP2K1/2])或ERK(ERK1/2 [MAPK1/3])的藥物通过协同抑制ERK激酶活性,在体外和体内逆转以高活性p-ERK为特征的一部分肝癌细胞系对索拉非尼的无应答。
- 高基础p-ERK水平见于约30%的肝癌。
临床怎么用
- 作者认为,高基础p-ERK水平的肿瘤最可能从索拉非尼联合MEK抑制剂治疗中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatment of liver cancer remains challenging because of a paucity of drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is approved as the standard therapy for patients with advanced hepatocellular carcinoma, but it only provides limited survival benefit. In this study we aimed to identify potential combination therapies to improve the clinical response to sorafenib. METHODS: To investigate the cause of the limited therapeutic effect of sorafenib, we performed a CRISPR-Cas9 based synthetic lethality screen to search for kinases whose knockout synergizes with sorafenib. Synergistic effects of sorafenib and selumetinib on cell apoptosis and phospho-ERK (p-ERK) were analyzed by caspase-3/7 apoptosis assay and western blot, respectively. p-ERK was measured by immunochemical analysis using a tissue microarray containing 78 liver cancer specimens. The in vivo effects of the combination were also measured in two xenograft models. RESULT: We found that suppression of ERK2 (MAPK1) sensitizes several liver cancer cell lines to sorafenib. Drugs inhibiting the MEK (MEK1/2 [MAP2K1/2]) or ERK (ERK1/2 [MAPK1/3]) kinases reverse unresponsiveness to sorafenib in vitro and in vivo in a subset of liver cancer cell lines characterized by high levels of active p-ERK, through synergistic inhibition of ERK kinase activity. CONCLUSION: Our data provide a combination strategy for treating liver cancer and suggest that tumors with high basal p-ERK levels, which are seen in approximately 30% of liver cancers, are most likely to benefit from such combinatorial treatment. LAY SUMMARY: Sorafenib is approved as the standard therapy for patients with advanced hepatocellular carcinoma, but only provides limited survival benefit. Herein, we found that inhibition of the kinase ERK2 increases the response to sorafenib in liver cancer. Our data indicate that a combination of sorafenib and a MEK inhibitor is most likely to be effective in tumors with high basal phospho-ERK levels.
引用
- Wang C, Jin H, Gao D, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol. 2018. PMID: 30030148. doi:10.1016/j.jhep.2018.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。